Menu
No results found.
Weekly Share Price & Valuation Overview
Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal medicine nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and other newborn and pediatric care, as well as newborn hearing screening, and support services in hospitals, pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 1.40B
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 1.67B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 1.94B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 472.72M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD 236.72M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 23.07
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 1.30
- Shares Outstanding
- 87.08M
- Float Shares
- 84.23M
- Implied Shares Outstanding
- 87.08M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
13.59%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
12.20%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
24.36%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
5.66%
- ROA Return on assets: net income ÷ total assets.
-
6.50%
- ROE Return on equity: net income ÷ shareholder equity.
-
14.27%
- Revenue Growth Year-over-year revenue growth.
-
-7.00%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
20.43%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.74
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.78
- Total Cash Cash and equivalents.
- USD 348.33M
- Total Debt Short + long-term interest-bearing debt.
- USD 649.56M
- Net Debt Total debt − cash (negative = net cash).
- USD 301.23M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 2.74
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD 244.55M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD 192.82M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
12.60%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
9.94%
- Cash Conversion (OpCF/EBITDA)
- 1.03
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.